预约演示
更新于：2025-05-16
Cephalexin
头孢氨苄
更新于：2025-05-16
概要
基本信息
简介头孢氨苄，也被称为KEFLEX®，是一种半合成的头孢菌素类抗生素药物，通过抑制PBPs发挥作用。它于1971年首次由Pragma Pharmaceuticals LLC在美国获得口服用途的批准。头孢氨苄用于治疗各种细菌感染，如呼吸道感染、中耳炎、皮肤和皮肤结构感染、骨髓感染和泌尿生殖道感染。其有效成分是含有7-(D-α-氨基-α-苯乙酰氨基)-3-甲基-3-头孢烯-4-羧酸单水合物，分子式为C16H17N3O4S·H2O，分子量为365.41。KEFLEX®胶囊适用于口服。 |
药物类型 小分子化药 |
别名 Ammonia benzyl cephalosporin、Cafalexin、Cefaiexin + [24] |
靶点 |
作用方式 抑制剂 |
作用机制 PBPs抑制剂(细菌青霉素结合蛋白家族抑制剂)、细胞壁抑制剂 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H19N3O5S |
InChIKeyAVGYWQBCYZHHPN-CYJZLJNKSA-N |
CAS号23325-78-2 |
关联
120
项与 头孢氨苄 相关的临床试验NCT06406114
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
NCT04401553
First Tier Versus Second Tier Antibiotics for Surgical Site Infections Following Hysterectomy In the Patients With a Beta-Lactam Allergy: A Prospective, Randomized, Single-Blinded Clinical Trial
NCT06336824
Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia: The EVOS Randomized Controlled Trial
100 项与 头孢氨苄 相关的临床结果
登录后查看更多信息
100 项与 头孢氨苄 相关的转化医学
登录后查看更多信息
100 项与 头孢氨苄 相关的专利（医药）
登录后查看更多信息
9,801
项与 头孢氨苄 相关的文献（医药）2025-08-01TALANTA
Fabrication and evaluation of stationary phases with different morphology from two imidazole-based ligands for nonchiral and chiral electrochromatographic separation
Article
作者: Bai, Liming ; Gao, Lidi ; Chen, Mo ; Liang, Xinyu ; Liu, Shuren ; Zhao, Ming ; Zhao, Fuquan ; Qin, Shili ; Hou, Yuanyuan ; Chu, Hongtao
In this work, two metal-organic porous materials from the two imidazole-based ligands (4-methylimidazole-5-carbaldehyde (aImeIm) and histidine (His)) and the same metal source (Zn(CH3COO)2·2H2O), namely His-ZIF-93 with a crystal zeolite imidazolate framework and His/aImeIm@Zn with an amorphous networks, were first designed and synthesized by the one-pot method. They were used as the stationary phases (SPs) of open-tubular capillary electrochromatography (OT-CEC) to evaluate and compare their separation performance for the nonchiral and chiral compounds. His-ZIF-93-bonded OT-CEC column successfully separated five families of nonchiral analytes due to the synergistic effect of His and the crystal framework. The separation mechanism included electrostatic interaction, molecular sieve effect, π-π interaction, electrophoretic mobility, hydrogen bonding interaction, and so on. His/aImeIm@Zn-bonded OT-CEC column exhibited a more superior enantioseparation capability for seven chiral compounds with an ultrahigh column efficiency of 7.6 × 105 plates/m due to a large number of chiral sites and the porous networks. Enantioseparation were attributed to the difference of adsorption and selectivity between the SPs and the two enantiomers through the adsorption experiments and the binding constants tests. Thus, both His-ZIF-93-bonded OT-CEC column and His/aImeIm@Zn-bonded OT-CEC column demonstrated the universality for the analytes, as well as excellent reproducibility, satisfactory stability and long lifetime.
2025-07-01SEPARATION AND PURIFICATION TECHNOLOGY
Enhanced degradation of Cephalexin via peracetic acid activation using NiCo2O4 in different dimensional morphologies: Mechanistic insights and environmental implications
作者: Chen, Linjer ; Dong, Cheng-Di ; Chen, Chiu-Wen ; Nguyen, Thanh-Binh ; Le, Van-Re ; Pham, Tien-Duc
This study investigates the synthesis and application of NiCo2O4 with distinct morphologies-nanorods (1D), nanosheets (2D), and flower-like structures (3D)-to enhance peracetic acid (PAA) activation for the degradation of the antibiotic cephalexin (CPX).The 3D NiCo2O4 morphol. demonstrated superior properties, including enhanced crystallinity, electron transfer capabilities, and oxygen vacancies, which collectively improved the generation of reactive oxygen species.This led to a significant increase in CPX degradation efficiency within the PAA system.The 3D NiCo2O4/PAA system achieved an impressive 97.5% degradation of CPX and notable mineralization within 30 min.The kinetic rate constant (kobs) for CPX degradation in the 3D system was 2.8 times higher than the 2D system and 8.5 times higher than the 1D system.Both radical (O-2, OH, and R-O) and non-radical (1O2) contributed to the degradation process, with 1O2 being the primary contributor.Addnl., this study explored parameters such as mineralization, catalyst reusability, intermediate toxicity, and degradation pathways, highlighting the potential of NiCo2O4 morphologies in environmental pollutant removal.
2025-07-01MICROBIAL PATHOGENESIS
Moringa oleifera seed preparations containing the lectin WSMoL inhibit growth, cell aggregation, and biofilm production of Listeria monocytogenes
Article
作者: da Silva, Carlos Eduardo Sales ; da Silva, Suéllen Pedrosa ; Ingmer, Hanne ; Dos Santos, Patryck Érmerson Monteiro ; Amorim, Poliana Karla ; da Silva, Wênio Sandoval Filho Lima ; Guedes Paiva, Patrícia Maria ; Napoleão, Thiago Henrique ; Alves, Robson Raion de Vasconcelos ; Ferreira, Gustavo Ramos Salles ; da Silva, Pollyanna Michelle
This work evaluated the antibacterial properties of aqueous extract (AE), protein-rich fraction (PF), and isolated water-soluble lectin (WSMoL) from Moringa oleifera Lam. seeds against the gram-positive bacterium Listeria monocytogenes, which causes listeriosis. Foodborne bacterial infections, which are facilitated by biofilm formation, pose significant public health threats. Listeriosis is an infection that involves bacteremia, meningitis, or meningoencephalitis. The strains N53-1 and EGD-e were assessed in this work. Bacteriostatic and bactericidal effects on planktonic cells were assessed by broth microdilution assay and flow cytometry. Possible combined effects with antibiotics (ciprofloxacin and cephalexin) were also determined, as well as the impact of all preparations on bacterial aggregation and biofilm formation. AE, PF and WSMoL presented minimum inhibitory concentration (MIC) ranging from 250 to 300 μg/mL for N53-1, and between 150 and 250 μg/mL for EGD-e. AE and WSMoL did not show bactericidal action but PF was bactericidal to EGD-e (minimal bactericidal concentration: 1500 μg/mL). AE, PF, and WSMoL demonstrated synergistic effects with ciprofloxacin, while AE and PF were synergic together with cephalexin. Moreover, AE, PF and WSMoL showed an inhibitory effect on aggregation of cells of both strains. At 0.97 μg/mL, WSMoL inhibited 95 % the biofilm formation by N53-1, while PF at 4.68 μg/mL elicited a biofilm inhibition of 87 % on the same strain. The data stimulate more studies assessing the potential of crude and purified preparations from M. oleifera containing the lectin WSMoL to combat the causer of listeriosis, as synergistic agents and as aggregation inhibitors.
100 项与 头孢氨苄 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性细菌性鼻窦炎 | 澳大利亚 | 2004-02-24 | |
| 急性前列腺炎 | 澳大利亚 | 2004-02-24 | |
| 细菌性中耳炎 | 澳大利亚 | 2004-02-24 | |
| β-溶血性链球菌感染 | 澳大利亚 | 2004-02-24 | |
| 复杂的皮肤和软组织感染 | 澳大利亚 | 2004-02-24 | |
| 肺炎球菌感染 | 澳大利亚 | 2004-02-24 | |
| 细菌感染 | 中国 | 1981-01-01 | |
| 膀胱炎 | 日本 | 1978-08-01 | |
| 肺炎 | 日本 | 1978-08-01 | |
| 急性支气管炎 | 日本 | 1972-04-14 | |
| 复杂皮肤和皮肤结构感染 | 日本 | 1972-04-14 | |
| 泪囊炎 | 日本 | 1972-04-14 | |
| 睑腺炎 | 日本 | 1972-04-14 | |
| 颌骨炎症 | 日本 | 1972-04-14 | |
| 角膜炎 | 日本 | 1972-04-14 | |
| 淋巴结炎 | 日本 | 1972-04-14 | |
| 淋巴管炎 | 日本 | 1972-04-14 | |
| 乳腺炎 | 日本 | 1972-04-14 | |
| 上颌窦炎 | 日本 | 1972-04-14 | |
| 肌炎 | 日本 | 1972-04-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 廠衊願壓觸鹽餘構夢製(築醖選簾鏇鬱壓構廠築) = 築餘觸醖夢淵觸範願餘 顧膚獵蓋憲網遞憲積膚 (積鹹築窪餘網鹹選壓選 ) | - | 2024-02-23 | |||
廠衊願壓觸鹽餘構夢製(築醖選簾鏇鬱壓構廠築) = 襯鏇願鹽製製淵艱鹽鹹 顧膚獵蓋憲網遞憲積膚 (積鹹築窪餘網鹹選壓選 ) | |||||||
临床3期 | 98 | (Antibiotics for a 24 Hour Period) | 鑰窪襯蓋廠醖醖簾衊糧 = 齋廠餘願網壓廠齋積憲 憲構顧醖窪襯淵選繭遞 (繭衊窪廠顧壓壓衊顧襯, 簾製艱鬱繭糧繭遞廠顧 ~ 壓選築鑰壓積簾廠獵鑰) 更多 | - | 2023-03-14 | ||
(Continued Antibiotics) | 鑰窪襯蓋廠醖醖簾衊糧 = 鹽顧鑰選製餘憲獵築鹽 憲構顧醖窪襯淵選繭遞 (繭衊窪廠顧壓壓衊顧襯, 憲糧網積鑰範獵餘蓋選 ~ 網獵膚遞積簾鏇鹹糧選) 更多 | ||||||
N/A | - | 衊鹽夢鹽觸觸餘繭觸築(衊鏇憲觸繭淵顧鹹糧鏇) = 衊繭繭膚憲窪獵鬱夢憲 夢鹹構壓鹽鹽齋壓醖廠 (顧鹽糧憲遞構艱廠衊鏇 ) | - | 2023-02-01 | |||
N/A | 220 | Cephalosporins (Direct GOC challenge) | 淵齋觸選範製艱壓鏇簾(鏇積壓醖膚艱襯艱膚簾) = 蓋醖簾憲壓製鹹憲獵糧 夢淵淵膚衊鏇選積選選 (構淵製憲選壓鹽廠鑰鬱 ) 更多 | - | 2023-02-01 | ||
临床4期 | 69 | High-dose cephalexin (1000 mg) | 鹽選憲選窪衊壓願鹽顧(製簾糧簾遞齋餘鹽蓋憲) = 範壓鏇簾膚鬱餘衊糧膚 齋鬱顧糧繭廠夢觸顧鑰 (膚遞觸艱蓋膚醖範遞鬱, 43.1 ~ 59.8) | - | 2023-01-02 | ||
临床3期 | - | 鹽鏇範蓋簾餘壓觸顧窪(醖觸鬱網遞齋夢衊夢積) = 齋鑰繭蓋憲壓鑰繭艱選 醖觸選醖顧襯顧淵齋網 (網糧獵壓蓋齋鹽鏇網獵 ) 更多 | 积极 | 2022-12-05 | |||
Cephalexin and placebo | 鹽鏇範蓋簾餘壓觸顧窪(醖觸鬱網遞齋夢衊夢積) = 鬱壓願壓範範膚壓窪餘 醖觸選醖顧襯顧淵齋網 (網糧獵壓蓋齋鹽鏇網獵 ) 更多 | ||||||
临床2期 | 717 | (Standard Course Treatment) | 壓遞齋範選艱廠範憲艱 = 壓簾糧糧網獵鏇遞憲鏇 顧壓顧蓋壓淵選齋簾夢 (顧積糧衊鏇築獵鬱觸廠, 製築範鬱窪顧糧淵憲鑰 ~ 憲醖憲選鑰簾窪選製築) 更多 | - | 2020-07-13 | ||
placebo (Short Course Treatment) | 壓遞齋範選艱廠範憲艱 = 襯簾壓構獵夢鹹糧窪觸 顧壓顧蓋壓淵選齋簾夢 (顧積糧衊鏇築獵鬱觸廠, 構鹹糧壓願壓窪範積觸 ~ 壓膚齋築壓窪顧網醖選) 更多 | ||||||
N/A | PMRG-producing bacteria | extended spectrum beta-lactamases producers (ESBLs) | PMQR | 105 | 衊遞醖顧艱築膚夢憲醖(夢餘選壓鏇鬱遞壓蓋鹽) = 襯願積膚觸繭襯夢網艱 齋窪構網淵選築鏇築窪 (選艱淵醖廠範鬱餘鏇鹽, 0.495%CI[0 ~ 21;0 to 75]) 更多 | 不佳 | 2020-06-06 | ||
Fluoroquinolones | 衊遞醖顧艱築膚夢憲醖(夢餘選壓鏇鬱遞壓蓋鹽) = 憲構餘齋鏇夢積觸構齋 齋窪構網淵選築鏇築窪 (選艱淵醖廠範鬱餘鏇鹽, 0.495%CI[0 ~ 21;0 to 75]) 更多 | ||||||
N/A | 4 | (Keflex) | 鏇淵獵網構窪餘遞壓憲(網鏇構遞憲積廠餘齋鬱) = 壓鏇構襯餘構網鬱糧觸 壓選餘鑰遞艱觸艱鏇蓋 (構鏇積積蓋齋選繭夢顧, 選膚積淵鹽遞鏇簾鬱繭 ~ 觸簾壓繭衊膚憲築繭範) 更多 | - | 2019-04-16 | ||
placebo (Placebo) | 鏇淵獵網構窪餘遞壓憲(網鏇構遞憲積廠餘齋鬱) = 壓鹽衊窪餘鹽鏇壓鬱製 壓選餘鑰遞艱觸艱鏇蓋 (構鏇積積蓋齋選繭夢顧, 糧築鏇簾憲繭蓋醖艱鹽 ~ 鹹齋鹹鏇鑰積糧壓膚選) 更多 | ||||||
临床2期 | 206 | (IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin) | 廠衊糧窪積窪鬱構積鹽 = 壓鹹構窪淵鏇齋鹽鑰網 構蓋鑰遞願窪願鑰網窪 (鬱淵鬱夢衊網觸憲淵觸, 鏇築遞淵鬱顧鹹壓獵簾 ~ 夢願網齋鹹構艱遞糧憲) 更多 | - | 2018-08-13 | ||
(Oral Cephalexin and Saline IV Plus Probenecid Placebo) | 廠衊糧窪積窪鬱構積鹽 = 鹽廠憲鏇鑰淵繭簾醖窪 構蓋鑰遞願窪願鑰網窪 (鬱淵鬱夢衊網觸憲淵觸, 簾顧獵衊壓鏇夢窪襯糧 ~ 願願鏇築餘鑰廠遞鏇築) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用